XLIFE-SCIENCES-AG
5.3.2021 08:50:09 CET | Business Wire | Press release
Xlife Sciences AG and Solothurn-based anfass Life Technologies AG have entered a joint venture. Hence, the jointly founded Quadira Biosciences AG has access to the 3D CoSeedis(TM) technology platform of abc biopply ag. This unique 3D cell technology enables the replication of human tissue for reliable testing and characterization of antibodies without animal testing. Xlife's technology platform for the development of antibodies will be used even more efficiently.
As of today, Xlife Sciences AG has already identified 30 compounds with blockbuster potential with its antibody screening platform. These therapeutic antibodies have already shown to be safe and effective in humans. Xlife can modify these antibodies with utmost accuracy and increase the quality of the active ingredient. These are mainly advanced, highly potent antibodies with higher cytotoxic activity and improved side effect profile for cancer therapy. The target market potential of the pre-selected antibodies is in the range of several billion US dollars.
With the collaboration of abc biopply, a portfolio company of anfass Life Technologies, the development process will be advanced significantly. Abc biopply developed a technology platform 3D CoSeedis(TM) that allows the testing and characterization in terms of efficacy of antibodies in 3D- cell cultures, also known as organoids, which are similar to animal or human tissue. This reduces or even eliminates animal testing and accelerates product development significantly. 3D CoSeedis(TM) differentiates itself with its unique homogeneity of produced spheroids and allows standardized mass production. This leads to simplified preclinical modelling of diseases. With this sustainable joint-venture, Quadira Biosciences AG could revolutionize cancer therapy.
About anfass Life Technologies AG
anfass Life Technologies AG invests in promising technologies in the fields of biotech, medical technology and diagnostics. The company also provides strategic and operational support to start-ups and SMEs in the life science sector and offers access to a broad expertise and a reliable network of selected partners. www.anfass.ch
abc biopply ag is a portfolio company of anfass Life Technologies AG. www.biopply.com
.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
IMPORTANT NOTE: The Annual General Meeting of Xlife Sciences AG will now take place on May 11, 2021, due to the Covid-19 measures of the federal government in written form by letter.
Language: |
English |
Company: |
Xlife Sciences AG Klausstrasse 19 8008 Zürich Switzerland |
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich EQS |
News ID: |
1173329 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006227/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor Secures Permanent Injunction in India Following Rulings in Europe and the United States12.8.2026 15:00:00 CEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890, hereinafter 'Seoul') and its affiliate Seoul Viosys Co., Ltd. (KOSDAQ: 092190), global opto-semiconductor technology companies, have obtained a permanent injunction enjoining infringement of Seoul’s opto-semiconductor patents in India, following similar injunction rulings in Europe and the United States. The Delhi High Court extended the injunction to the managing director as well. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812490873/en/ Patented opto-semiconductor light-output enhancement technology applied in the lawsuits (left) and WICOP technology (right) (Graphic: Seoul Viosys) These rulings are expected to significantly impact the global opto-semiconductor industry, a market worth roughly USD 200 billion that is expanding from automotive lighting and displays into optical communications for AI applications. In India, Seoul Viosys won a final judgment against Ornate
Rimini Street Expands C-Suite Leadership for Growth with Appointment of Two Proven Industry Veterans as Chief Operating Officer and Chief Delivery Officer12.8.2026 15:00:00 CEST | Press release
Rimini Street appoints Keith Costello as EVP and Chief Operating Officer and Alexander Guasch as EVP and Chief Delivery Officer Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Keith Costello as chief operating officer (COO) and Alexander Guasch as chief delivery officer (CDO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812127732/en/ Rimini Street Expands C-Suite Leadership for Growth with Appointment of Two Proven Industry Veterans as Chief Operating Officer and Chief Delivery Officer New COO Brings Proven Experience Scaling Organizations for Growth Keith Costello brings decades of experience building and scaling global enterprise software and services organizations, including leading teams of tens of thousands and managing businesses generating billions of dollars i
Brightfin Helps Federal Agencies Plan IT Finances Faster and Cut Telecom Costs Through Knox’s FedRAMP Platform12.8.2026 15:00:00 CEST | Press release
Partnership gives government organizations a compliant path to faster financial planning, more strategic decision-making, operational efficiency, and lower IT and telecom costs Brightfin today announced that its technology spend management solutions are now available to U.S. federal agencies through Knox’s FedRAMP Authorized cloud platform. Deploying on Knox gives public sector organizations a compliant path to faster financial planning cycles, more strategic decision-making, and lower IT and telecom costs, the same discipline commercial enterprises rely on. Brightfin is actively working with Knox toward achieving FedRAMP certification. Federal agencies have long struggled with IT spend data that is siloed and disconnected, limiting their ability to manage hardware and software assets and their associated costs. The result is a reactive posture, scrambling to keep pace with evolving government requirements rather than getting ahead of them. Built natively on ServiceNow, Brightfin turns
illumynt Appoints Matt Popieniuck as Vice President of Customer Success & Delivery12.8.2026 14:00:00 CEST | Press release
28-year Dell Technologies veteran, most recently leading services sustainability strategy, joins to own end-to-end program execution as illumynt scales its AI hardware lifecycle business illumynt, a technology-driven leader in AI hardware lifecycle recovery and IT asset disposition (ITAD), today announced that Matt Popieniuck has joined the company as Vice President of Customer Success & Delivery, effective August 2026. He reports to CEO Jörg Herbarth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812482293/en/ Matthew Popieniuck, Vice President of Customer Success and Delivery. Popieniuck joins illumynt after 28 years at Dell Technologies, where he progressed from group leadership through senior and principal program management roles before moving into services sustainability strategy. In that most recent chapter, he worked on the question now driving illumynt's market: what happens to enterprise technology after its fi
Ant Group launches AQ for Doctor, bringing an AI-powered workstation to millions of physicians12.8.2026 13:44:00 CEST | Press release
Ant Group today officially upgraded its physician platform, Haodf for Doctor, into AQ for Doctor, an AI-powered workstation designed to support physicians across every stage of clinical practice—from online consultations and patient management to clinical decision support and medical research. The platform is fully integrated with Ant Group's flagship AI health app, AQ, which serves more than 100 million users as of August 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812917154/en/ Ant Group launches AQ for Doctor, bringing an AI-powered workstation to millions of physicians. Connecting doctors and patients through one AI platform "AI will never replace doctors," said Zhang Junjie, Vice President of Ant Group and Head of the Health Business. "But AI can become a trusted assistant for healthcare professionals. Our goal is to build a reliable and practical AI workstation for China's more than five million physicians—
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom